579 related articles for article (PubMed ID: 20518577)
1. Human papillomavirus vaccines: current status and future prospects.
Garland SM; Smith JS
Drugs; 2010 Jun; 70(9):1079-98. PubMed ID: 20518577
[TBL] [Abstract][Full Text] [Related]
2. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
3. Cervical cancer vaccine development.
Frazer IH
Sex Health; 2010 Sep; 7(3):230-4. PubMed ID: 20719210
[TBL] [Abstract][Full Text] [Related]
4. Age-appropriate use of human papillomavirus vaccines in the U.S.
Castle PE; Fetterman B; Akhtar I; Husain M; Gold MA; Guido R; Glass AG; Kinney W
Gynecol Oncol; 2009 Aug; 114(2):365-9. PubMed ID: 19464729
[TBL] [Abstract][Full Text] [Related]
5. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
6. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.
McKeage K; Romanowski B
Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus vaccines: an update for gynecologists.
Ault KA
Clin Obstet Gynecol; 2008 Sep; 51(3):527-32. PubMed ID: 18677145
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.
Sigurdsson K; Sigvaldason H; Gudmundsdottir T; Sigurdsson R; Briem H
Acta Obstet Gynecol Scand; 2009; 88(1):27-35. PubMed ID: 19031282
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus vaccines versus cervical cancer screening.
Stanley M
Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):388-94. PubMed ID: 18538554
[TBL] [Abstract][Full Text] [Related]
10. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica.
Gonzalez P; Hildesheim A; Herrero R; Katki H; Wacholder S; Porras C; Safaeian M; Jimenez S; Darragh TM; Cortes B; Befano B; Schiffman M; Carvajal L; Palefsky J; Schiller J; Ocampo R; Schussler J; Lowy D; Guillen D; Stoler MH; Quint W; Morales J; Avila C; Rodriguez AC; Kreimer AR;
Vaccine; 2015 Apr; 33(18):2141-51. PubMed ID: 25796338
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic HPV vaccination: past, present, and future.
Castle PE; Maza M
Epidemiol Infect; 2016 Feb; 144(3):449-68. PubMed ID: 26429676
[TBL] [Abstract][Full Text] [Related]
13. Cancers attributable to human papillomavirus infection.
Grulich AE; Jin F; Conway EL; Stein AN; Hocking J
Sex Health; 2010 Sep; 7(3):244-52. PubMed ID: 20719211
[TBL] [Abstract][Full Text] [Related]
14. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy.
Brotherton JM; Kaldor JM; Garland SM
Sex Health; 2010 Sep; 7(3):310-9. PubMed ID: 20719220
[TBL] [Abstract][Full Text] [Related]
15. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
Szarewski A
Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
[TBL] [Abstract][Full Text] [Related]
16. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
18. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
Prescrire Int; 2008 Jun; 17(95):103-4. PubMed ID: 18623911
[TBL] [Abstract][Full Text] [Related]
19. Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age.
Harper DM
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S11-7. PubMed ID: 18649932
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
